LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Aandelen Lijst・Altimmune Inc

Altimmune Inc

Gesloten

3.03 -5.31

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.02

Max

3.06

Belangrijke statistieken
By Trading Economics
Inkomsten	-8.3M -27M
Verkoop	21K 26K
Winstmarge	-105,223.077
Werknemers	57
EBITDA	-10M -29M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+321.88% upside

Dividenden
By Dow Jones
Volgende Winsten	12 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-73M 448M
Vorige openingsprijs	8.34
Vorige sluitingsprijs	3.03

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.365 / 6.0486 Steun & Weerstand

Altimmune Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

27 mrt 2026, 17:33 UTC

Belangrijke Nieuwsgebeurtenissen

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 mrt 2026, 17:00 UTC

Belangrijke Nieuwsgebeurtenissen

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 mrt 2026, 16:03 UTC

Belangrijke Nieuwsgebeurtenissen

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27 mrt 2026, 14:50 UTC

Belangrijke Marktbewegers

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27 mrt 2026, 14:37 UTC

Acquisities, Fusies, Overnames

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27 mrt 2026, 14:29 UTC

Belangrijke Nieuwsgebeurtenissen

EU Finance Ministers Tally Economic Hit of Iran War -- Update

27 mrt 2026, 14:16 UTC

Belangrijke Nieuwsgebeurtenissen

The Week in Oil: Mixed Signals Over U.S.-Iran Talks Keep Traders Wary

27 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 19:16 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 mrt 2026, 19:07 UTC

Marktinformatie

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 mrt 2026, 19:04 UTC

Marktinformatie

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 mrt 2026, 19:03 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 19:02 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 mrt 2026, 18:12 UTC

Marktinformatie

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 mrt 2026, 17:36 UTC

Belangrijke Nieuwsgebeurtenissen

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 mrt 2026, 17:34 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 mrt 2026, 17:29 UTC

Marktinformatie

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 mrt 2026, 16:38 UTC

Marktinformatie

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 mrt 2026, 16:32 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 mrt 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

27 mrt 2026, 15:43 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 mrt 2026, 15:25 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 15:25 UTC

Marktinformatie

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27 mrt 2026, 15:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27 mrt 2026, 15:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27 mrt 2026, 15:00 UTC

Belangrijke Nieuwsgebeurtenissen

Fed's Barkin Says Iran War Raising Economic Uncertainty

27 mrt 2026, 14:36 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27 mrt 2026, 14:26 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

27 mrt 2026, 14:14 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

27 mrt 2026, 14:14 UTC

Marktinformatie

Global Energy Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Altimmune Inc Prognose

Koersdoel

By TipRanks

321.88% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.5 USD 321.88%

Hoogste 25 USD

Laagste 4.01 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Altimmune Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

Buy

Hold

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Altimmune Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.365 / 6.0486Steun & Weerstand

Recent bullish events outweigh bearish events.

All events are bearish.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.